Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company developing allogeneic CAR T (AlloCAR T) therapies for cancer and autoimmune disease. The ALLO news feed on Stock Titan aggregates company announcements, clinical updates, and regulatory disclosures so readers can follow how its AlloCAR T pipeline progresses through development.
News about Allogene frequently highlights key milestones in its major programs. For oncology, updates include progress in the pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma, including trial design changes, site activations, and planned interim analyses focused on minimal residual disease (MRD) conversion. For autoimmune disease, releases cover the Phase 1 RESOLUTION trial of ALLO-329, a dual CD19/CD70 AlloCAR T candidate that incorporates the company’s Dagger® technology and is being studied across multiple rheumatologic indications.
Investors and observers can also find news on ALLO-316 in renal cell carcinoma through the TRAVERSE trial, including early clinical response data and discussions with regulators about potential pivotal development. Additional items include quarterly financial results, cash runway commentary, participation in investor and medical conferences, and 8-K summaries of material events such as changes in lymphodepletion strategy or intellectual property developments involving licensed TALEN-based gene-editing technology.
By following ALLO news, readers can track clinical catalysts, safety and biomarker findings, regulatory interactions, and corporate updates that may influence perceptions of Allogene’s AlloCAR T platform and its potential applications in hematologic malignancies, solid tumors, and autoimmune diseases.
Allogene Therapeutics (ALLO) provided a corporate update and reported Q3 2020 financial results, reflecting continued progress in developing its AlloCAR T therapies. The company ended Q3 with $1.0 billion in cash and expects to submit several Investigational New Drug applications, including for ALLO-316 and ALLO-715, by the end of 2020. Initial clinical data from the UNIVERSAL trial for ALLO-715 in multiple myeloma will be announced in Q4 2020. Full-year net losses are projected between $260 million and $280 million, including significant stock-based compensation.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) will announce its Q3 2020 financial results on November 4, 2020, prior to market opening. A conference call and audio webcast will follow at 5:30 AM PT / 8:30 AM ET. The company focuses on developing allogeneic CAR T cell therapies, aiming to provide readily available treatment options for cancer patients. A replay of the webcast will be available for 30 days on their website. The press release contains forward-looking statements about the company's future and the potential benefits of its therapies.
Allogene Therapeutics (Nasdaq: ALLO) has entered a five-year collaboration with The University of Texas MD Anderson Cancer Center to evaluate multiple AlloCAR T candidates targeting various tumors. This partnership aims to expedite the development of allogeneic CAR T therapies, leveraging MD Anderson's clinical trial expertise and Allogene's cell therapy knowledge. The collaboration will entail joint oversight of preclinical and clinical studies, with Allogene funding the initiative.
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotech firm, announced its participation in the Jefferies Virtual Cell Therapy Summit on October 6, 2020. The event is scheduled for 12:30 PM PT/3:30 PM ET and will focus on the development of allogeneic CAR T therapies for cancer. A live webcast will be available on the company's website, with a replay for 30 days. Allogene aims to provide 'off-the-shelf' CAR T therapies, enhancing patient access and scalability in treatment.
Allogene Therapeutics reported promising initial Phase 1 results from the ALLO-501 ALPHA trial, showcasing a 75% overall response rate and 44% complete response rate in CAR T naïve relapsed/refractory non-Hodgkin lymphoma patients. Ongoing trials for ALLO-501A and ALLO-715 are also being developed, with initial data expected in Q4 2020. The company reported a net loss of $61.0 million for Q2 2020, while ending the quarter with $1.1 billion in cash and equivalents, ensuring robust financial support for upcoming clinical trials.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) will announce its second quarter 2020 financial results on August 5, 2020, prior to market opening. A live audio webcast and conference call is scheduled for 5:30 AM PT/8:30 AM ET. The event will be accessible via the Company's website, where a replay will also be available for approximately 30 days. The press release emphasizes the company's focus on developing allogeneic CAR T therapies for cancer, aiming to provide accessible treatment options to patients.
Notch Therapeutics has appointed David Main as President and CEO, enhancing its leadership to drive the development of innovative, off-the-shelf T cell therapies from stem cells. Main brings over 30 years of biopharmaceutical experience, previously leading Aquinox Pharmaceuticals through successful phases of development and public listing. Notch's advanced Engineered Thymic Niche (ETN) technology aims to create universal T cell therapies, and the company is currently partnered with Allogene Therapeutics (NASDAQ: ALLO) to focus on CAR-targeted therapies for hematologic cancers.
Allogene Therapeutics (Nasdaq: ALLO) announced that Dr. Ton Schumacher, Principal Investigator at the Netherlands Cancer Institute and chair of its Scientific Advisory Board, received the prestigious Stevin Prize for his research in cancer immunotherapy. This award, worth 2.5 million euros, recognizes impactful scientific contributions and will fund further research into predicting T cell responses to cancer antigens. Dr. Schumacher's work is pivotal in advancing AlloCAR T™ therapies aimed at transforming cancer treatment. His recognition enhances Allogene's reputation and leadership in the field.
Allogene Therapeutics (Nasdaq: ALLO) announced preclinical findings on DLL3-targeted AlloCAR T therapy for small cell lung cancer (SCLC) and its iTurboCAR technology at the AACR annual meeting. These studies provide scientific support for the AlloCAR and TurboCAR platforms. Findings indicated engineered T cells targeting DLL3 exhibited long-term efficacy without causing brain damage. Additionally, the iTurboCAR technology allows controlled cytokine activation, enhancing CAR T cell potency. Both innovations underline Allogene's commitment to advancing allogeneic cell therapies.
Allogene Therapeutics (Nasdaq: ALLO) announced promising preclinical results for its investigational AlloCAR T therapy, ALLO-819, targeting FLT3 for acute myeloid leukemia (AML). The study, published in Molecular Therapy, demonstrated significant anti-leukemic activity without off-target effects. ALLO-819 employs engineered healthy donor T lymphocytes and includes a safety mechanism. The therapy aims to offer a novel treatment option for AML patients, who often face poor prognoses and limited treatments. Allogene holds global rights for ALLO-819, developed in collaboration with Cellectis and Pfizer.
FAQ
What is the current stock price of Allogene Therapeutics (ALLO)?
What is the market cap of Allogene Therapeutics (ALLO)?
